 JAK3 is predominantly expressed in hematopoietic cells and has been a promising therapeutic target for the treatment of B cell lymphoma . In this study a new class of thieno 3 2

@highlight Novel thieno 3 2 
@highlight  pyrimidines as potent covalent JAK3 inhibitors.
@highlight displayed strong inhibitory potency against JAK3 rather than BTK.
@highlight showed low cytotoxic activity against normal PBMC cells.
@highlight induced the apoptosis of B lymphoma cells in a dose and time dependent manner and repressed JAK STAT cascade.
